278 related articles for article (PubMed ID: 1143978)
1. The timing of tuberculin tests in relation to immunization with live viral vaccines.
Brickman HF; Beaudry PH; Marks MI
Pediatrics; 1975 Mar; 55(3):392-6. PubMed ID: 1143978
[TBL] [Abstract][Full Text] [Related]
2. Experience with live rubella virus vaccine combined with live vaccines against measles and mumps.
Smorodintsev AA; Nasibov MN; Jakovleva NV
Bull World Health Organ; 1970; 42(2):283-9. PubMed ID: 5310140
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of mumps virus given alone or in combination with live vaccines against measles and rubella.
Nasibov MN; Yakovleva NV; Smorodintsev AA
Prog Immunobiol Stand; 1970; 4():676-82. PubMed ID: 5482205
[No Abstract] [Full Text] [Related]
4. [Field trial with a new human diploid cell vaccine (HDCV) against measles, mumps and rubella].
Just M; Berger R; Glück R; Wegmann A
Schweiz Med Wochenschr; 1985 Nov; 115(48):1727-30. PubMed ID: 4081704
[TBL] [Abstract][Full Text] [Related]
5. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
Gerike E; Tischer A
Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
[TBL] [Abstract][Full Text] [Related]
6. Protection of mumps in children with various underlying diseases: application of a live attenuated mumps and trivalent measles-rubella-mumps (MRM) vaccines in these children.
Kanesaki T; Baba K; Tsuda N; Yabuuchi H; Yamanishi K; Takahashi M
Biken J; 1986 Dec; 29(3-4):63-71. PubMed ID: 3304276
[TBL] [Abstract][Full Text] [Related]
7. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
[TBL] [Abstract][Full Text] [Related]
8. Measles, mumps and rubella: control by vaccination.
van Druten JA; de Boo T; Plantinga AD
Dev Biol Stand; 1986; 65():53-63. PubMed ID: 3556777
[TBL] [Abstract][Full Text] [Related]
9. [Clinico-immunologic evaluation of a trivalent vaccine against measles, rubella and mumps].
Schettini F; Manzionna MM; De Mattia D; Amendola F; Di Bitonto G
Minerva Pediatr; 1989 Mar; 41(3):117-22. PubMed ID: 2747598
[TBL] [Abstract][Full Text] [Related]
10. [Prevalence of antibodies and vaccination against measles, mumps and rubella in Polish population].
Janaszek-Seydlitz W; Bucholc B; Wysokińska T; Górska P; Gniadek G
Przegl Epidemiol; 2003; 57(2):281-8. PubMed ID: 12910596
[TBL] [Abstract][Full Text] [Related]
11. [Morbidity, vaccine coverage and immunity against measles, mumps and rubella in a Gallician population from 2 to 5 years old].
Vázquez Fernández E; López Rois F; Vázquez Carrete JA; Gómez Tato B; Alvarez Ares M
An Esp Pediatr; 1987 Jul; 27(1):27-31. PubMed ID: 3662251
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
Sultana R; Rahman MM; Hassan Z; Hassan MS
Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
[TBL] [Abstract][Full Text] [Related]
13. Administration of measles-mumps-rubella vaccination with other childhood schedule vaccines.
Heath TC; Burgess MA; O'Brien ED
Commun Dis Intell; 1998 Aug; 22(8):159. PubMed ID: 9735551
[No Abstract] [Full Text] [Related]
14. Combination measles, mumps, rubella and varicella vaccine.
Arbeter AM; Baker L; Starr SE; Levine BL; Books E; Plotkin SA
Pediatrics; 1986 Oct; 78(4 Pt 2):742-7. PubMed ID: 3763291
[TBL] [Abstract][Full Text] [Related]
15. [Certain problems with limits of immunity against measles, mumps and rubella].
Magdzik W
Przegl Epidemiol; 1993; 47(1-2):47-53. PubMed ID: 8351387
[TBL] [Abstract][Full Text] [Related]
16. CHRONOVAC VOYAGEUR: A study of the immune response to yellow fever vaccine among infants previously immunized against measles.
Goujon C; Gougeon ML; Tondeur L; Poirier B; Seffer V; Desprès P; Consigny PH; Vray M;
Vaccine; 2017 Oct; 35(45):6166-6171. PubMed ID: 28958813
[TBL] [Abstract][Full Text] [Related]
17. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
[TBL] [Abstract][Full Text] [Related]
18. Serological evaluation of 52 children immunized with the combined measles, mumps and rubella vaccine.
Topal B; Kanra G; Ceyhan M
Turk J Pediatr; 1991; 33(1):13-8. PubMed ID: 1844171
[TBL] [Abstract][Full Text] [Related]
19. Persistence of immunity following monovalent and combined live measles, mumps, and rubella virus vaccines.
Weibel RE; Buynak EB; Stokes J; Hilleman MR
Pediatrics; 1973 Mar; 51(3):467-75. PubMed ID: 4707864
[No Abstract] [Full Text] [Related]
20. The immunogenicity and reactogenicity of the trivalent vaccine, Trimovax, indicated for prevention of measles, mumps, and rubella, in 12-month-old children in Belarus.
Samoilovich EO; Kapustik LA; Feldman EV; Yermolovich MA; Svirchevskaya AJ; Zakharenko DF; Fletcher MA; Titov LP
Cent Eur J Public Health; 2000 Aug; 8(3):160-3. PubMed ID: 10965439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
